 Obviously, the changes that we have implemented for multiple myeloma patients during the COVID-19 pandemic are, in my opinion, going to have some impact over the long term, mid and long term. For instance, when it comes to telemedicine, I believe this is here to stay. And probably, in the future, we will continue to practice telemedicine with these patients and avoid any unnecessary visit to the clinic or to the hospital. When it comes to the changes that we have implemented from a therapeutic point of view, let's say, for instance, postponing or delaying auto transplant, I don't believe this will have an impact on the outcome of the patient or on their survival because we already know that based on clinical trials that this should not impact the survival of these patients. Obviously, some patients would ask, well, if this has no impact on overall survival, why should I undergo auto transplant? Well, it's a very complicated question and it has been a matter of debate within the myeloma community and between experts. Nevertheless, we know that auto transplant has an advantage in terms of progression for survival. So it allows to delay disease progression. So I think the recommendation today, although we can postpone or delay the auto transplant procedure, I think the recommendation is to stick to the application and delivering auto transplant for those patients who are eligible. When it comes to other therapeutic changes like dexametazone, dose reduction, or for instance, switching to oral drugs, I think many of these changes will stay, especially that they can have a positive impact on the quality of life of the patient and on reducing side effects. So this is really good news.